GTS Securities’s BridgeBio Pharma BBIO Stock Holding History

GTS Securities’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-26,300	Closed	-$694K	–	4040
2023 Q3	$694K	Buy	+26,300	New	+$746K	﹤0.01%	2301

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

GTS Securities's BBIO Position: Q2 2026 in Review

GTS Securities sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 3,446 shares — an estimated $256K sold.

GTS Securities first reported a position in BBIO in Q3 2025 and held it in 2 quarters. The position peaked at $293K in Q3 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

GTS Securities reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
GTS Securities sold 3,446 BridgeBio Pharma shares in Q2 2026, an estimated $256K.
GTS Securities first reported a position in BridgeBio Pharma in Q3 2025 and held it in 2 quarters.
GTS Securities's BridgeBio Pharma position peaked at $293K in Q3 2025.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.